About Cerenome / About Us
CNS oncology is our whole company.
Cerenome exists to change the trajectory of central nervous system (CNS) cancer, one of the hardest problems in oncology and one where survival has barely moved in 50 years.
One mission, one focus.
Our mission is to improve outcomes for people with CNS cancers by uniting precision diagnostics, targeted therapeutics, and clinical data as one platform. Our vision is bigger than any single program: to bend the survival curve, and to prove these cancers can be solved as one connected system.

The Platform
This is what solvable looks like.
Cerenome develops and commercializes precision diagnostics and targeted radiotherapeutics for CNS cancers. Each capability is stronger because the others exist. Diagnostics inform treatment, therapeutics generate data, and that data sharpens both.
Diagnostics
Diagnostics find and characterize the disease from a fluid sample.
Therapeutics
Therapeutics reach the tumor where most treatments can’t.
Data Insights
Data learns from every case to sharpen the next.
How Cerenome has evolved.
Cerenome represents the evolution of work that began at Plus Therapeutics in 2020. As Plus Therapeutics, the company spent years focused on cancers of the brain and central nervous system. Over time, that focus sharpened into a conviction: These cancers are best understood, and best treated, as one connected system. Today, as Cerenome, we carry that conviction forward. The same science, the same team, now built around a single integrated platform.

“We want to be the company that sees the survival curve going up and say, ‘Hey, we did that.’”
Marc Hedrick, MD
President and CEO of Cerenome
Fueled by conviction.
Russell Bradley, President and General Manager of CNSide® Diagnostics, on what makes the science, the company, and the platform unique.
Why Houston.
Cerenome is built in Houston, within reach of the Texas Medical Center. And it’s operational, not just locational: The CNSide® tumor-cell enumeration (TCE) assay is run in CNSide Diagnostics’ CLIA-licensed, CAP-accredited Houston laboratory.
Texas backs cancer innovation directly through CPRIT, the state’s cancer research institute, which funds part of our therapeutic program. Being here means proximity to the clinicians, institutions, and research infrastructure that CNS cancer work depends on.
The record so far.
~190M
Diagnostics, in the clinic.
CNSide® is CLIA-licensed and CAP-accredited, available across all 50 states in the U.S. and reimbursed across approximately 190 million covered lives.*
1
Peer-reviewed science.
Phase 1 REYOBIQ™ results in recurrent glioblastoma were published in Nature Communications (Brenner et al, 2025).
$23.9M
Non-dilutive funding.
ReSPECT-LM is backed by a $17.6M CPRIT grant, ReSPECT-GBM by a $3.3M award from the National Cancer Institute, and ReSPECT-PBC by a $3M U.S. Department of Defense grant.
*Coverage depends on test type, each plan’s medical policy, and the member’s benefits.
A team built for this.
Behind the platform is a focused team of scientists, clinicians, engineers, and technicians who chose depth over breadth. People who came to work on CNS cancer, and only CNS cancer.